Jones Financial Companies Lllp Reduces Stake in Johnson & Johnson $JNJ

Key Points

• Jones Financial Companies Lllp significantly reduced its stake in Johnson & Johnson by 73.7% in Q1, now holding 120,136 shares valued at approximately $19.90 million.
• Several hedge funds adjusted their positions in Johnson & Johnson, with notable increases from Lantz Financial LLC and Apexium Financial LP during the same quarter.
• Johnson & Johnson recently announced a quarterly dividend of $1.30 per share, reflecting a annualized yield of 2.9% amidst a strong financial performance during the last quarter.

Jones Financial Companies Lllp lessened its holdings in Johnson & Johnson (NYSE:JNJ - Free Report) by 73.7% in the 1st quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 120,136 shares of the company's stock after selling 336,611 shares during the quarter. Jones Financial Companies Lllp's holdings in Johnson & Johnson were worth $19,904,000 at the end of the most recent reporting period.

Other large investors have also modified their holdings of the company. Highline Wealth Partners LLC grew its stake in shares of Johnson & Johnson by 51.8% during the first quarter. Highline Wealth Partners LLC now owns 252 shares of the company's stock worth $42,000 after acquiring an additional 86 shares during the last quarter. Stone House Investment Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at approximately $47,000. 1248 Management LLC acquired a new position in Johnson & Johnson in the first quarter valued at approximately $48,000. von Borstel & Associates Inc. acquired a new position in Johnson & Johnson in the first quarter valued at approximately $49,000. Finally, Capital A Wealth Management LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at approximately $50,000. Hedge funds and other institutional investors own 69.55% of the company's stock.

Johnson & Johnson Price Performance

Shares of JNJ traded down $0.13 during trading hours on Monday, hitting $178.30. 8,325,117 shares of the stock were exchanged, compared to its average volume of 7,659,331. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.76 and a current ratio of 1.01. Johnson & Johnson has a 12-month low of $140.68 and a 12-month high of $181.16. The company has a market cap of $429.40 billion, a price-to-earnings ratio of 19.07, a price-to-earnings-growth ratio of 2.27 and a beta of 0.40. The stock's 50-day moving average price is $169.09 and its two-hundred day moving average price is $160.90.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings results on Wednesday, July 16th. The company reported $2.77 EPS for the quarter, topping the consensus estimate of $2.68 by $0.09. The firm had revenue of $23.74 billion during the quarter, compared to analysts' expectations of $22.85 billion. Johnson & Johnson had a return on equity of 32.49% and a net margin of 25.00%.The firm's revenue for the quarter was up 5.8% on a year-over-year basis. During the same period in the previous year, the business earned $2.82 earnings per share. Johnson & Johnson has set its FY 2025 guidance at 10.800-10.900 EPS. Research analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Tuesday, September 9th. Shareholders of record on Tuesday, August 26th will be issued a $1.30 dividend. This represents a $5.20 annualized dividend and a yield of 2.9%. The ex-dividend date is Tuesday, August 26th. Johnson & Johnson's dividend payout ratio is presently 55.61%.

Wall Street Analyst Weigh In

A number of analysts have recently commented on the company. Bank of America boosted their price objective on Johnson & Johnson from $161.00 to $175.00 and gave the company a "neutral" rating in a research report on Thursday, July 17th. Erste Group Bank upgraded Johnson & Johnson from a "hold" rating to a "buy" rating in a research report on Wednesday, July 23rd. Barclays boosted their price objective on Johnson & Johnson from $165.00 to $176.00 and gave the company an "equal weight" rating in a research report on Thursday, July 17th. Leerink Partners cut Johnson & Johnson from an "outperform" rating to a "market perform" rating and cut their price objective for the company from $169.00 to $153.00 in a research report on Tuesday, May 13th. Finally, Piper Sandler reiterated an "overweight" rating on shares of Johnson & Johnson in a research report on Thursday, July 17th. Two investment analysts have rated the stock with a Strong Buy rating, nine have issued a Buy rating and nine have assigned a Hold rating to the stock. According to MarketBeat.com, Johnson & Johnson currently has a consensus rating of "Moderate Buy" and an average price target of $176.29.

Insider Transactions at Johnson & Johnson

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of the company's stock in a transaction on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total value of $10,041,108.51. Following the completion of the sale, the executive vice president directly owned 178,013 shares in the company, valued at $31,652,491.53. This represents a 24.08% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 0.16% of the stock is currently owned by insiders.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.